



I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, Washington, DC 20231" on November 7, 2002.

Date

Name:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Leland F. WILSON et al.

Serial No.: 09/919,471

Group Art Unit: 1617

Filing Date: July 27, 2001

Examiner: San Ming R. HUI

Title: AS-NEEDED ADMINISTRATION OF ORALLY ACTIVE ANDROGENIC AGENTS
TO ENHANCE FEMALE SEXUAL DESIRE AND RESPONSIVENESS

RECEIVED

NOV 19 2002

TECH CENTER 1600/2900

Atty Dkt No. 9050-0053
PATENT

H/A
SC
11-27-02

AMENDMENT UNDER 37 CFR § 1.111

Commissioner for Patents
Washington, DC 20231

Sir:

This Amendment responds to the May 7, 2002, Office Action for the above-identified application. Applicants respectfully request reconsideration of the application in view of the following amendments and remarks. As this Amendment is accompanied by a three-month extension of time and appropriate fee, the Amendment is timely filed pursuant to 35 U.S.C. § 133 and 37 C.F.R. § 1.136.

AMENDMENTS

IN THE SPECIFICATION:

Please amend the paragraph at page 10, lines 8 to 21 as indicated in Appendix A. After entry of the amendment, the paragraph will read as follows:

Other androgenic agents that have oral activity, and whose oral activity can be enhanced by admixture with a lipoidal vehicle, include those mentioned in U.S. Patent No. 4,147,783 to van der Vies, including, by way of example, the following esters of testosterone and DHT: decanoate, pentadecanoate, undecanoate, pelargonate, tridecanoate, palmitate, caprate, isocaprate, α -methylcaprate, β -methylcaprate, laurate, α -methylpelargonate, β -methylpelargonate, β,β -

11/15/2002 ABGMAH1-00000030-09919471

04-PC-B053

160.00 op